Korro Bio and Frequency Therapeutics Announce Merger Agreement
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs
Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation
Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026
Companies to host conference call today at 8:30 a.m. ET
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel geneti
